Cardiome Pharma Shares Edge Up

Cardiome Pharma shares were higher 2% on Tuesday after the company said it is closer to launching its Xydalba treatment for acute bacterial skin and skin structure infections in the U.K. after receiving an established price from the Secretary of State for Health.

“The creation of an established price does not guarantee reimbursement in the UK, but it is a critical step in preparation for launch by allowing Cardiome to start negotiating with individual hospitals to gain formulary access for Xydalba,” said Hugues Sachot, senior VP of commercial.

Cardiome expects to make its first commercial sale in the UK before the end of the year. The company has the treatment under license from Allergan (AGN).